Pharmascience Canada now launches an injectable solution of METHOTREXATE

Pharmascience Canada launches ^PrMETHOTREXATE Injection, BP. This treatment offers sterile, single-use pre-filled syringes to patients.

^PrMETHOTREXATEMethotrexate Injection, BP 25 mg/mL is supplied as follows:

• 5 mg/0.3 mL as a single-use pre-filled syringe
• 10 mg/ 0.4 mL as a single-use pre-filled syringe
• 15 mg/ 0.6 mL as a single-use pre-filled syringe
• 20 mg/ 0.8 mL as a single-use pre-filled syringe
• 25 mg/ 1.0 mL as a single-use pre-filled syringe

^PrMethotrexate Injection, BP belongs to a group of medicines known as antimetabolites. It is used in high doses to treat certain types of cancers, including breast cancer, non-Hodgkin’s lymphoma, and leukemia. At lower doses, it may also be used to treat severe psoriasis and severe rheumatoid arthritis.

^PrMethotrexate Injection, BP is indicated in the following diseases where standard therapeutic interventions fail:

• Severe disabling psoriasis/psoriatic arthritis
• Severe disabling rheumatoid arthritis (RA)
• Severe disabling seronegative arthritis.

With this dosage form manufactured in Candiac, Pharmascience Canada becomes the sole manufacturer and distributor of this drug.

“At Pharmascience, we take enormous pride in providing support and high-quality solutions for all our patients. With the launch of ^PrMETHOTREXATE Injection, BP in pre-fill syringe of 25 mg/mL to our portfolio of antineoplastic drugs & Disease-Modifying Antirheumatic Drug (DMARDs) products, patients in Canada can benefit from an affordable, easy to administer and accessible option to help manage their disease,” said Mike Dutton, Vice President, and General Manager of Pharmascience Canada.

ABOUT PHARMASCIENCE INC.

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada’s top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada.

Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2023, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada’s Top Employers for Young People as part of Canada’s Top 100 Employers. Pharmascience is now certified as a Great Place to Work for a second year in a row.

For product information, please contact Pharmascience’s Medical Information Department at 1-888-550-6060.